Scleral Histopathologic Findings of Hurler-Scheie Syndrome with Refractory Glaucoma

Kara A. Dolezal; Adam Jacobson; Cagri G. Besirli; Victor Elner; Brenda L. Bohnsack

doi:10.1001/jamaophthalmol.2021.5806

Scleral Histopathologic Findings of Hurler-Scheie Syndrome with Refractory Glaucoma

Kara A. Dolezal, Adam Jacobson, Cagri G. Besirli, Victor Elner, Brenda L. Bohnsack^*

^*Corresponding author for this work

Ophthalmology

Research output: Contribution to journal › Letter › peer-review

1 Scopus citations

Original language	English (US)
Pages (from-to)	285-287
Number of pages	3
Journal	JAMA ophthalmology
Volume	140
Issue number	3
DOIs	https://doi.org/10.1001/jamaophthalmol.2021.5806
State	Published - Mar 2022

Funding

ConflictofInterestDisclosures:DrHarperreportedpersonalfeesfromRegeneron. Dr Moshfeghi reported personal fees from Bayer, Novartis, Akebia, and Regeneron, as well as grants from Genentech. No other disclosures were reported.

ASJC Scopus subject areas

Ophthalmology

Access to Document

10.1001/jamaophthalmol.2021.5806

Cite this

@article{09e4fb610f7148f3927d0a764b82c7c3,

title = "Scleral Histopathologic Findings of Hurler-Scheie Syndrome with Refractory Glaucoma",

author = "Dolezal, {Kara A.} and Adam Jacobson and Besirli, {Cagri G.} and Victor Elner and Bohnsack, {Brenda L.}",

note = "Funding Information: ConflictofInterestDisclosures:DrHarperreportedpersonalfeesfromRegeneron. Dr Moshfeghi reported personal fees from Bayer, Novartis, Akebia, and Regeneron, as well as grants from Genentech. No other disclosures were reported.",

year = "2022",

month = mar,

doi = "10.1001/jamaophthalmol.2021.5806",

language = "English (US)",

volume = "140",

pages = "285--287",

journal = "JAMA ophthalmology",

issn = "2168-6165",

publisher = "American Medical Association",

number = "3",

}

TY - JOUR

T1 - Scleral Histopathologic Findings of Hurler-Scheie Syndrome with Refractory Glaucoma

AU - Dolezal, Kara A.

AU - Jacobson, Adam

AU - Besirli, Cagri G.

AU - Elner, Victor

AU - Bohnsack, Brenda L.

N1 - Funding Information: ConflictofInterestDisclosures:DrHarperreportedpersonalfeesfromRegeneron. Dr Moshfeghi reported personal fees from Bayer, Novartis, Akebia, and Regeneron, as well as grants from Genentech. No other disclosures were reported.

PY - 2022/3

Y1 - 2022/3

UR - http://www.scopus.com/inward/record.url?scp=85123385956&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85123385956&partnerID=8YFLogxK

U2 - 10.1001/jamaophthalmol.2021.5806

DO - 10.1001/jamaophthalmol.2021.5806

M3 - Letter

C2 - 35050321

AN - SCOPUS:85123385956

SN - 2168-6165

VL - 140

SP - 285

EP - 287

JO - JAMA ophthalmology

JF - JAMA ophthalmology

IS - 3

ER -

Scleral Histopathologic Findings of Hurler-Scheie Syndrome with Refractory Glaucoma

Funding

ASJC Scopus subject areas

Access to Document

Other files and links

Cite this